Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 6Withdrawn 4Terminated 3Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 2Thoracic 1Sarcoma 1Lymphoid 1Genitourinary 1

Conditions

Breast Neoplasms 48Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 24Ovarian Neoplasms 23Fallopian Tube Neoplasms 21Triple Negative Breast Neoplasms 15Breast Neoplasms, Male 14Brenner Tumor 12Melanoma 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Lung Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma of Lung 7Urinary Bladder Neoplasms 6Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Stomach Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Cholangiocarcinoma 4Pleural Effusion, Malignant 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Transitional Cell 3Uveal Melanoma 2Tongue Neoplasms 2Thymoma 2

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Neoplasms × Taxes × Clear all
NCT03564691 2025-10-07

MK-4830-001

Merck Sharp & Dohme LLC

Phase 1 Completed
470 enrolled
Tumor-Agnostic

Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
56 enrolled 19 charts
GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03918278 2025-06-25

MK-0482-001

Merck Sharp & Dohme LLC

Phase 1 Completed
222 enrolled
Tumor-Agnostic

Neoplasms

NCT03275818 2022-06-07

ABRADES

Grupo Espanol de Investigacion en Sarcomas

Phase 2 Completed
69 enrolled
Sarcoma

Neoplasms, Recurrence, Sarcoma, Sarcoma, Ewing, Desmoid Tumors, Desmoplastic Small Round Cell Tumor

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

M.D. Anderson Cancer Center

Phase 1 Completed
78 enrolled
Tumor-Agnostic

Neoplasms

NCT01161186 2012-10-11

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡